Tyler Jacks is a David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT), a long-time HHMI investigator, and Founding Director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis, and treatment of cancer.
[1] Dr. Jacks is a member of the board of directors of Thermo Fisher Scientific and Amgen, two of the major biotechnology corporations in the world.
[4] Tyler Jacks graduated magna cum laude with Highest Honors in biology from Harvard University in 1983[5] and earned a PhD in biochemistry from the University of California, San Francisco in 1988 under the guidance of Nobel Laureate Harold Varmus.
[15] He has pioneered the use of gene-targeting technology in mice to study cancer-associated genes and to construct mouse models of many human cancer types.
The lab focuses on using a series of mouse strains carrying engineered mutations known to be involved in human cancer.